Transition Therapeutics Inc. (TSE: TTH) has entered into a partnership with the Juvenile Diabetes Research Foundation (JDRF) to support a clinical development plan for Transition's diabetes regenerative product, GLP1-I.N.T.™
The world's leading charitable funder of type 1 diabetes research, JDRF, will provide milestone-driven payments of up to U.S. $4 million to the project over two years, facilitating the rapid advancement of the GLP1-I.N.T.™ diabetes regenerative product into Phase II clinical trials in type 1 diabetes patients.
Find more details from Transition Therapeutics, Inc. press release and the JDRF press release.
Emerging as a major focus for diabetes research and drug development, regenerative medicine is an approach that has the potential to offer therapeutics that can restore the body's ability to produce insulin on its own, thereby reducing both the need for insulin injections and the diabetes-associated complications which include heart disease, kidney disease and blindness.
Comment Preview